Clinical application status and development of TNBC (BC) monoclonal antibody

Zian Ding

doi:10.62051/ewg6ta51

Authors

Zian Ding

DOI:

https://doi.org/10.62051/ewg6ta51

Keywords:

TNBC; Monoclonal antibody; Clinical application; TROP-2; PD-1; CTLA-4.

Abstract

A particular subtype of breast cancer known as triple-negative breast cancer (TNBC) is distinguished by the lack of ER, PR, and HER2 expression, culminating in HER2-targeted therapy with a poor prognosis and inadequate conventional hormone therapy. With the growing comprehension of the biological traits of TNBC in recent years, treatment strategies have gradually developed, particularly the use of mAb medications, which has renewed optimism for the treatment of TNBC. Because of its high specificity and targeting, mAb drugs have shown remarkable efficacy and potential in cancer treatment. An extensive examination of the clinical usage of mAb medications in the treatment of TNBC is given in this review. summarizing clinical trial data on key drugs such as PD-1/PD-L1 and TROP-2-targeted drugs, demonstrating the significant effect of these drugs in prolonging PFS and OS in patients. At the same time, new therapeutic targets besides PD-1 and TROP-2 are discussed, as well as the potential advantages of combination therapy strategies. The clinical application of mAb medications in TNBC is thoroughly examined in this study., summarizing clinical trial data on key drugs such as PD-1/PD-L1 and TROP-2-targeted drugs, demonstrating the significant effect of these drugs in prolonging PFS and OS in patients. At the same time, new therapeutic targets besides PD-1 and TROP-2 are discussed, as well as the potential advantages of combination therapy strategies.

Downloads

Download data is not yet available.

References

[1] Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol, 2022, 17: 181-204.

[2] Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J, 2021, 27(1): 8-16.

[3] Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 2020, 22(1): 61.

[4] Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol, 2021, 18(6): 345-362.

[5] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434.

[6] Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011, 121(7): 2750-2767.

[7] Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418): 61-70.

[8] Shen Y, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in triple-negative breast cancer. Front Oncol, 2019, 9: 1290.

[9] Denkert C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 2010, 28(1): 105-113.

[10] Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer, 2016, 16(2): 110-120.

[11] Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol, 2012, 12(5): 615-622.

[12] Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab emtansine in HER2-positive breast cancer. N Engl J Med, 2014, 371(1): 106-116.

[13] Modi S, Saura C, Yamashita T, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med, 2020, 382(7): 610-621.

[14] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res, 2020, 10(3): 727-742.

[15] Cortés J, Cesano A, Dent R, et al. First interim analysis of the phase III KEYNOTE-522 trial of pembrolizumab with neoadjuvant and adjuvant chemotherapy versus placebo with neoadjuvant and adjuvant chemotherapy for early triple-negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, December 10-14, 2019, San Antonio, TX. Abstract GS2-04.

[16] Qiu S, Zhang J, Wang Z, et al. Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochim Biophys Acta Rev Cancer, 2023, 1878(4): 188902.

[17] Bardia A, et al. Sacituzumab govitecan in previously treated metastatic triple-negative breast cancer. N Engl J Med, 2021, 384(16): 1529-1541.

[18] Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood, 2018, 131(1): 58-67.

[19] KEYNOTE-522. Pembrolizumab plus Chemotherapy in Early Triple-Negative Breast Cancer. N Engl J Med, 2020.

[20] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med, 2018.

[21] Sun Y, et al. Tucatinib, trastuzumab, and capecitabine in overexpressing HER2 metastatic breast cancer (HER2CLIMB): A randomized clinical trial. JAMA Oncol, 2020. DOI: 10.1001/jamaoncol.2019.5297.

[22] Cheng Y, Liu Y, Zhang W, et al. EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). ESMO, 2023. Abstract LBA93.

[23] Shun P, Li J, Feng X, et al. Final analysis of the CHOICE-01 study: Toripalimab combined with chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced NSCLC without EGFR or ALK mutations. J Clin Oncol, 2022, 40(28): 3296-3307.

[24] Liao L, et al. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer. Cancer Res, 2023, 83(3): 471-484.

[25] Tarantino P, Antonarelli G, Ascione L, Curigliano G. Investigational immunomodulatory drugs for enhancement of triple-negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opin Investig Drugs, 2022, 31(6): 499-513.

[26] Gao F, et al. Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer. Acta Pharm Sin B, 2024.